NCT00645424

A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol

A Randomized, 12-Week, Open Labeled Study To Evaluate The Efficacy And Safety Of Once Daily Atorvastatin In Diabetes Mellitus Type 2 With Hyperlipidemia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 155 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of atorvastatin for the treatment of Taiwanese patients with diabetes and high cholesterol.

Conditions

• Hyperlipidemias

Interventions

Type	Name	Description
DRUG	atorvastatin	Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
DRUG	atorvastatin	Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
DRUG	atorvastatin	Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks

Timeline

• Start date: 2003-12-01
• Completion: 2004-10-01
• First posted: 2008-03-27
• Last updated: 2021-02-18

Locations

5 sites across 1 country: Taiwan